Dopamine analog amide

C - Chemistry – Metallurgy – 07 – C

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

167/179, 260/519

C07C 233/20 (2006.01) A61K 31/16 (2006.01) A61K 31/165 (2006.01) C07D 233/64 (2006.01) A61K 38/00 (2006.01)

Patent

CA 1340475

The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.

614666

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Dopamine analog amide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dopamine analog amide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dopamine analog amide will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1291314

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.